Search
Standard BioTools Inc
LABAdd to Watchlist
0.913USD
+0.046+5.32%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
356.16MMarket Cap
4.57P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+5.32%
5 Days
+24.34%
1 Month
-28.12%
6 Months
-28.12%
Year to Date
-28.68%
1 Year
-32.38%
Key Figures
0.850Open
0.929High
4.45MVolume
4.57P/E TTM
LossP/E Dynamic
--Dividend TTM
1.14%Turnover Ratio
0.867Prev. Close
0.850Low
3.32MTurnover
LossP/E Static
0.63P/B
0.00%Div Yield TTM
-8.22%ROA
1.72052wk High
0.67Volume Ratio
-184.90MNet Profit
390.14MShares
0.1999EPS TTM
1.37Beta
-9.86%ROE
0.87052wk Low
9.14%Amplitude
53.48%Gross Margin
356.16MMarket Cap
-7.78Reward/Risk
4.08%Risk Rate
TradingKey Stock Score of Standard BioTools Inc
Currency: USD Updated: 2026-07-02Key Insights
Standard BioTools Inc's fundamentals are relatively very healthy, and its growth potential is good.Its valuation is considered fairly valued, ranking 86 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 1.55.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Standard BioTools Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Standard BioTools Inc Highlights
StrengthsRisks
Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Growing
The company is in a growing phase, with the latest annual income totaling USD 85.33M.
Overvalued
The company’s latest PE is 4.57, at a high 3-year percentile range.
Institutional Buying
The latest institutional holdings are 317.36M shares, increasing 0.24% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 50.85M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 1.91.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
1.550
Target Price
+78.82%
Upside Space
Standard BioTools Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Standard BioTools Inc Info
Standard BioTools Inc. develops, manufactures and sells a diversified range of instrumentation, consumables, and services that help scientists and biomedical researchers. The Company's segments include Proteomics and Genomics. The Proteomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes instruments, consumables, software, and services based upon technologies used in the identification of genes (DNA, RNA) and their functions. The Company works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. It offers a diverse range of instrumentation, consumables, and services that generate data across early discovery, translational and clinical research.
Ticker SymbolLAB
CompanyStandard BioTools Inc
CEOEgholm (Michael)
Websitehttps://www.standardbio.com/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Standard BioTools Inc (LAB)?
The current price of Standard BioTools Inc (LAB) is 0.91.
What is the symbol of Standard BioTools Inc?
The ticker symbol of Standard BioTools Inc is LAB.
What is the 52-week high of Standard BioTools Inc?
The 52-week high of Standard BioTools Inc is 1.72.
What is the 52-week low of Standard BioTools Inc?
The 52-week low of Standard BioTools Inc is 0.87.
What is the market capitalization of Standard BioTools Inc?
The market capitalization of Standard BioTools Inc is 356.16M.
Is Standard BioTools Inc (LAB) currently rated as Buy, Hold, or Sell?
According to analysts, Standard BioTools Inc (LAB) has an overall rating of Buy, with a price target of 1.55.
What is the Earnings Per Share (EPS TTM) of Standard BioTools Inc (LAB)?
The Earnings Per Share (EPS TTM) of Standard BioTools Inc (LAB) is -0.20.